Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Neomorph, Inc
Bristol-Myers Squibb
Xencor, Inc.
Nuvectis Pharma, Inc.
Arcus Biosciences, Inc.
Tizona Therapeutics, Inc
HiberCell, Inc.
Kura Oncology, Inc.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Columbia University
Molecure S.A.
Dana-Farber Cancer Institute